Strikingly, when stratifying patients by both AML‐MRC subtype and TP53 mutation status, patient outcomes largely grouped together by TP53 mutation status, not AML‐MRC subtype (Figure 3A,B). The gene discussed is TP53; the disease is acute myeloid leukemia.